masoprocol has been researched along with Parkinson Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardes, G; Krol, ES; Munir, O | 1 |
| Caldwell, GA; Caldwell, KA; Daniels, MJ; Felli, I; Ferrie, JJ; Gould, NS; Grandori, R; Haney, CM; Ischiropoulos, H; Kim, H; Krol, ES; Moons, R; Murrali, MG; Natalello, A; Nourse, JB; Pan, B; Petersson, EJ; Pierattelli, R; Rhoades, E; Sainati, V; Schiavina, M; Sobott, F; Uversky, VN | 1 |
| Afzal, M; Ara, G; Jyoti, S; Siddique, YH | 1 |
3 other study(ies) available for masoprocol and Parkinson Disease
| Article | Year |
|---|---|
The effect of diphenylethane side-chain substituents on dibenzocyclohexadiene formation and their inhibition of α-synuclein aggregation in vitro.
Topics: alpha-Synuclein; Catechols; Cyclization; Humans; Masoprocol; Parkinson Disease | 2023 |
Cyclized NDGA modifies dynamic α-synuclein monomers preventing aggregation and toxicity.
Topics: alpha-Synuclein; Amyloid; Animals; Caenorhabditis elegans; Cell Membrane; Humans; Masoprocol; Parkinson Disease; Phospholipids; Protein Aggregation, Pathological | 2019 |
The dietary supplementation of nordihydroguaiaretic acid (NDGA) delayed the loss of climbing ability in Drosophila model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Brain; Dietary Supplements; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drosophila melanogaster; Drosophila Proteins; Free Radicals; Humans; Locomotion; Masoprocol; Mutation; Parkinson Disease; Phytotherapy; Plant Extracts | 2012 |